DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Down 5.1% in August

DBV Technologies S.A. (NASDAQ:DBVT) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 278,800 shares, a decrease of 5.1% from the August 15th total of 293,700 shares. Based on an average daily volume of 50,900 shares, the days-to-cover ratio is presently 5.5 days. Currently, 0.3% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DBVT shares. JMP Securities upped their target price on DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a research report on Wednesday, July 31st. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. Finally, StockNews.com began coverage on shares of DBV Technologies in a report on Thursday. They set a “hold” rating for the company.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. raised its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Price Performance

Shares of DBVT opened at $0.69 on Thursday. The stock has a market capitalization of $66.68 million, a PE ratio of -0.82 and a beta of 0.68. The business’s fifty day moving average price is $0.88 and its 200 day moving average price is $1.12. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.97.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same period last year, the firm posted ($0.26) earnings per share. As a group, research analysts anticipate that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.